How much funding has Atea Pharmaceuticals raised?

Atea Pharmaceuticals has raised $215.0M in total funding, most recently a Series D round.

When was Atea Pharmaceuticals founded?

Atea Pharmaceuticals was founded in 2014.

Where is Atea Pharmaceuticals headquartered?

Atea Pharmaceuticals is headquartered in Boston, Massachusetts, United States.

What industry is Atea Pharmaceuticals in?

Atea Pharmaceuticals operates in Biotech, Healthcare.

How many employees does Atea Pharmaceuticals have?

Atea Pharmaceuticals has 51-200 employees.

Atea Pharmaceuticals

Q: Who are Atea Pharmaceuticals's investors?

Atea Pharmaceuticals's investors include Bain Capital Life Sciences, RA Capital Management, Perceptive Advisors, Rock Springs Capital.

IPO

Committed to the discovery, development and commercialization of oral direct-acting antiviral therapies.

Public · Boston, United States · Founded 2014 · $215.0M raised

Biotech

Healthcare

Headquarters: Boston, Massachusetts
Employees: 51–200
Founded: 2014
Business Model: B2B
Website: ateapharma.com

Total Funding: $215.0M
Last Round: $215.0M Series DMay 2020
Rounds: 1
Type: Public

About

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral direct-acting antiviral therapies for serious viral diseases with unmet medical needs. Its lead program is a fixed-dose combination of bemnifosbuvir and ruzasvir in Phase 3 development for hepatitis C virus, with topline data from the C-BEYOND trial expected mid-2026. Atea also has early-stage programs targeting dengue and RSV.

Summary

Atea Pharmaceuticals is a Biotech company based in Boston, United States, founded in 2014. It has raised $215.0M in total across 1 round, most recently a $215.0M Series D round in May 2020. Investors include Bain Capital Life Sciences, RA Capital Management and Perceptive Advisors.

LinkedIn X (Twitter)